ClinicalTrials.gg
TerminatedNCT03433703Updated Dec 6, 2019Results posted

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

A Phase 2 interventional study of Lenvatinib in Carcinoma, Hepatocellular, sponsored by Eisai Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-06.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Study recruitment was stopped due to difficulty in enrolling the targeted number of participants.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.

Enrollment
114th of 121
8 · median 48
Started
2018
with 5 others
Phase 2
66 of 121
33 open now
Registered
6th of 121
by date

Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 114th largest by enrollment, is one of 6 that started in 2018, is one of 66 in phase 2, and was the 6th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing lenvatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma (uHCC) participants.

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • Unresectable hepatocellular carcinoma
  • Lenvatinib
  • E7080
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have confirmed diagnosis of unresectable Hepatocellular Carcinoma (uHCC) with any of the following criteria:

    1. or cytologically confirmed diagnosis of uHCC
    2. Clinically confirmed diagnosis of uHCC according to American Association for the Study of Liver Diseases criteria, including cirrhosis of any etiology or with chronic or C infection criteria
  • At least one measurable target lesion regardless if hepatic or non-hepatic according to modified () meeting the following criteria:

    1. Hepatic lesion

      • The lesion can be accurately measured in at least one dimension as ≥1.0 centimeters (cm) (viable tumor for typical; and longest diameter for atypical), and
      • The lesion is suitable for repeat measurement,
    2. Nonhepatic lesion

      • Lymph node lesion that measures at least one dimension as ≥1.5 cm in the short axis
      • Non-nodal lesion that measures ≥1.0 cm in the longest diameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.
  • Participants categorized on the Barcelona Clinic Liver Cancer staging system to Stage B (not applicable for transarterial chemoembolization) or Stage C
  • Adequate bone marrow function, liver function, blood coagulation function, renal function, and pancreatic function as assessed by laboratory tests.
  • Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP ≤150/90 millimeters of mercury (mmHg) at Screening and no change in antihypertensive therapy within 1 week prior to Cycle 1/Day 1
  • A
  • Performance Status of 0 or 1
  • Survival expectation of 12 weeks or longer before starting study drug

Key Exclusion Criteria:

  • Imaging findings for HCC corresponding to any of the following:

    1. HCC with ≥50% liver occupation
    2. Clear invasion into the bile duct
    3. Portal vein invasion at the main portal branch (Vp4)
  • Participants who have received any systemic chemotherapy, including sorafenib, regorafenib or other anti-vascular endothelial growth factor therapy, nivolumab, or any systemic anticancer agents, including lenvatinib, for advanced/uHCC.
  • Participants who have received any anticancer therapy (including surgery, percutaneous ethanol injection, radio frequency ablation, transarterial [chemo] embolization, hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or radiotherapy) or any blood enhancing treatment (including blood transfusion, blood products, or agents that stimulate blood cell production, e.g., granulocyte colony-stimulating factor) within 28 days prior to the first dose of lenvatinib study treatment.
  • Participants who have not recovered from toxicities as a result of prior anticancer therapy such as the local hepatic injection chemotherapy or any prior therapy for other cancer types.
  • Significant cardiovascular impairment within 6 months of the first dose of study drug
  • Prolongation of corrected for heart rate using Fridericia's correction (QTcF) to >480 milliseconds (ms)
  • Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator
  • Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic monitoring
  • Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least half teaspoon) within 28 days prior to the first dose of lenvatinib study treatment
  • Gastric or esophageal varices that require treatment
  • Active (except for HCC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 36 months
  • Any history of or current brain or subdural
  • Participants having >1+ proteinuria on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein ≥1 grams/24 hour will be ineligible
  • Arterial-portal venous shunt or arterial-venous shunt preventing proper diagnosis of tumor
  • Any medical or other condition that in the opinion of the investigator would preclude the participant's participation in a clinical study
  • Known intolerance to lenvatinib or any of the
  • positive or active infection requiring treatment (except for hepatitis virus)
  • Any history of drug or alcohol dependency or abuse within the prior 2 years
  • Major surgery within 3 weeks prior to the first dose of lenvatinib study treatment or scheduled for surgery during the study
  • Participant has had a liver transplant
  • Females who are breastfeeding or pregnant at Screening or Baseline
  • Females of who within 28 days before study entry did not use a highly effective method of or do not agree to use a highly effective method of contraception throughout the entire study period
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Lenvatinib

    Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.

    Drug: Lenvatinib

Interventions

  • Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)

    Also known as: LENVIMA®, E7080

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From the first dose of study drug up to 28 days after the last dose of study drug (approximately 3 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of first dose of study treatment to the date of death from any cause. Participants who are lost to follow-up are censored at the last date the participant was known to be alive, and participants who remain alive are censored at the time of data cutoff. OS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

    Time frame: From first dose date until date of death from any cause (approximately 3 months)

  2. Progression-free Survival (PFS)

    PFS based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) (and including the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 conventions for non-hepatic lesions) is defined as the time from the date of the first dose of first-line lenvatinib treatment to the date of the first documentation of PD, or the date of death during the subsequent systemic TPC, whichever occurs first. PD is defined at least 20% increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameters of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

    Time frame: From first dose date until PD or date of death from any cause (approximately 3 months)

  3. Time to Progression (TTP)

    TTP based on mRECIST (and including the RECIST 1.1 conventions for non-hepatic lesions) is defined as the time from the date of the first dose of first-line lenvatinib treatment to the date of the first documentation of disease progression during subsequent systemic TPC. PD is defined at least 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. TTP was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

    Time frame: From first dose date until PD (approximately 3 months)

07

Results

Posted Dec 6, 2019
Limitations and caveats
The study was terminated due to difficulty in enrolling the targeted number of participants. Secondary endpoints could not be analyzed because of very low sample size. No safety concerns involved in decision to stop enrollment.

Participant flow

Participants took part in the study at 3 investigative sites in the United States from 26 April 2018 to 07 January 2019.

Participant flow — Overall Study
MilestoneLenvatinib
Started2
Completed0
Not completed2
Withdrew: Study terminated by sponsor2

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From the first dose of study drug up to 28 days after the last dose of study drug (approximately 3 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsLenvatinib
TEAEs1
SAEs1
SecondaryOverall Survival (OS)

OS is defined as the time from the date of first dose of study treatment to the date of death from any cause. Participants who are lost to follow-up are censored at the last date the participant was known to be alive, and participants who remain alive are censored at the time of data cutoff. OS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

Time frame:
From first dose date until date of death from any cause (approximately 3 months)
Reported as:
Median · months
Overall Survival (OS)
monthsLenvatinib
Overall Survival (OS)NA (NA to NA)
SecondaryProgression-free Survival (PFS)

PFS based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) (and including the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 conventions for non-hepatic lesions) is defined as the time from the date of the first dose of first-line lenvatinib treatment to the date of the first documentation of PD, or the date of death during the subsequent systemic TPC, whichever occurs first. PD is defined at least 20% increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameters of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

Time frame:
From first dose date until PD or date of death from any cause (approximately 3 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsLenvatinib
Progression-free Survival (PFS)NA (NA to NA)
SecondaryTime to Progression (TTP)

TTP based on mRECIST (and including the RECIST 1.1 conventions for non-hepatic lesions) is defined as the time from the date of the first dose of first-line lenvatinib treatment to the date of the first documentation of disease progression during subsequent systemic TPC. PD is defined at least 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. TTP was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

Time frame:
From first dose date until PD (approximately 3 months)
Reported as:
Median · months
Time to Progression (TTP)
monthsLenvatinib
Time to Progression (TTP)NA (NA to NA)

Adverse events

Collected over From the first dose of study drug up to 28 days after the last dose of study drug (approximately 3 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib0/2 (0%)1/2 (50%)1/2 (50%)
Most frequent serious events
Most frequent serious events
EventLenvatinib
Hepatic encephalopathyNervous system disorders1/2
Most frequent other events
Most frequent other events
EventLenvatinib
Urinary tract infectionInfections and infestations1/2
EpistaxisRespiratory, thoracic and mediastinal disorders1/2
Skin ulcerSkin and subcutaneous tissue disorders1/2

Baseline characteristics

The Safety Analysis Set (Full Analysis Set) included all participants who received at least 1 dose of the lenvatinib treatment.

Age, Categorical
Age, Categorical(Participants)Lenvatinib
<=18 years0
Between 18 and 65 years1
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib
Female0
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib
Hispanic or Latino0
Not Hispanic or Latino2
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jan 2019, 8 months.

Results were first posted in Dec 2019, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 14, 2018
StartActual
Apr 26, 2018
Primary completionActual
Jan 7, 2019
CompletionActual
Jan 7, 2019
Results first posted
Dec 6, 2019
Last update
Dec 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03433703
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Apr 26, 2018
Primary completion
Jan 7, 2019
Completion
Jan 7, 2019
Results posted
Dec 6, 2019
Last update
Dec 6, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion